Hub : Traits :

Schizophrenia

541 significantly associated models · 150 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 7715776 9571422 2 1 1.9e-08 2.1e-07 7.8e-01 100 RERE
2 1 149672809 150480373 1 1 3.4e-07 1.1e-08 6.9e-03 78 HIST2H2BF
3 1 242590540 244359621 3 2 1.8e-10 1.0e-07 1.9e-01 94 CEP170 SDCCAG8
4 2 57689942 59167557 1 1 4.0e-07 9.5e-12 3.4e-06 54 FANCL
5 2 96675166 98024837 1 1 9.9e-09 4.4e-06 1.2e-02 70 LMAN2L
6 2 197134790 202078494 10 3 2.1e-13 1.1e-11 8.6e-01 100 ANKRD44 C2orf47 SF3B1
7 2 233047291 234434621 1 1 1.5e-07 1.2e-13 1.2e-07 49 C2orf82
8 3 1442951 3792945 1 1 2.0e-07 3.9e-09 3.1e-04 62 CNTN4
9 3 36235084 37614424 1 1 1.3e-07 5.7e-10 5.7e-04 69 AC011816.1
10 3 51616334 53778875 13 1 4.1e-11 6.3e-10 2.3e-01 96 ITIH4-AS1
11 3 63121945 64546545 1 1 9.1e-10 1.5e-09 1.0e+00 100 THOC7
12 3 135273949 137261517 2 1 1.6e-10 3.4e-11 4.7e-03 82 PCCB
13 3 179627093 181023400 1 1 2.7e-07 2.9e-10 8.3e-05 61 TTC14
14 4 169845720 171339965 1 1 3.7e-08 3.7e-08 1.0e+00 100 CLCN3
15 5 59467203 60936935 3 1 2.0e-10 1.8e-11 2.2e-03 79 ERCC8
16 5 136972187 138474788 2 1 3.9e-11 2.8e-08 1.8e-02 82 FAM53C
17 5 138860604 140337279 1 1 9.3e-08 3.8e-06 3.6e-06 0 CYSTM1
18 6 42702570 44115567 1 1 3.0e-07 5.3e-07 1.5e-03 60 ABCC10
19 6 83082766 84576263 1 1 8.4e-08 6.9e-08 1.5e-05 36 DOPEY1
20 7 1161158 2977732 2 1 4.8e-09 9.4e-13 8.6e-06 61 MAD1L1
21 7 86260816 87670741 1 1 3.3e-07 1.4e-09 3.9e-09 5 TP53TG1
22 7 99591418 100979310 1 1 1.2e-07 1.3e-06 3.8e-01 97 GIGYF1
23 7 109603832 111895681 2 1 7.4e-11 4.0e-12 1.1e-03 78 IMMP2L
24 8 9646560 11045161 1 1 3.1e-07 2.9e-07 6.7e-04 56 RP11-981G7.6
25 8 16315069 17851248 2 2 2.5e-07 3.1e-09 1.3e-02 82 VPS37A ZDHHC2
26 8 142839492 144323692 1 1 6.6e-09 7.9e-12 4.1e-07 45 BAI1
27 10 103313599 105647095 10 6 2.2e-13 4.7e-15 1.0e+00 100 ARL3 AS3MT CNNM2 CYP17A1-AS1 NT5C2
28 11 45929961 47632707 3 1 1.4e-09 6.9e-10 3.0e-02 88 ATG13
29 11 56784574 58202974 1 1 2.3e-11 1.9e-06 3.4e-02 80 TMX2
30 11 63316786 64707978 1 1 3.3e-09 2.1e-05 8.6e-01 100 PPP1R14B
31 11 130038487 131476599 2 1 1.9e-11 1.1e-11 3.1e-02 90 SNX19
32 11 133079948 134525648 1 1 5.4e-11 9.0e-12 6.4e-03 84 IGSF9B
33 12 1204676 2805632 2 2 4.7e-14 1.2e-17 8.0e-05 79 CACNA2D4 DCP1B
34 12 110175537 111634281 2 1 1.7e-08 3.8e-09 4.5e-02 88 VPS29
35 12 122713991 124591385 8 1 5.1e-11 1.7e-11 1.0e+00 100 CDK2AP1
36 14 34867304 36283925 1 1 4.1e-07 6.7e-07 4.8e-01 98 PPP2R3C
37 14 70676661 72273020 1 1 9.2e-09 2.0e-08 2.9e-01 96 PCNX
38 14 103161201 105211221 11 1 3.8e-12 4.9e-12 2.3e-01 97 KLC1
39 15 78135979 79537269 1 1 1.4e-07 3.7e-09 2.4e-03 74 PSMA4
40 15 83167559 84013521 1 1 7.9e-08 1.2e-07 4.0e-02 85 CPEB1
41 15 84151637 85895721 10 1 1.1e-09 1.7e-08 8.1e-01 100 AC103965.1
42 15 90718541 92135418 2 1 1.4e-10 5.4e-11 5.0e-02 91 FES
43 16 28825605 30823047 8 1 1.3e-08 3.1e-08 6.0e-01 99 MAPK3
44 16 88946761 90172696 2 1 1.6e-08 1.8e-07 4.9e-03 71 CPNE7
45 17 857257 2249904 1 1 5.0e-10 9.5e-09 2.1e-08 5 RILP
46 17 17017584 18512255 3 1 5.1e-08 2.6e-08 4.2e-03 74 TOM1L2
47 19 18408222 20432930 6 1 1.2e-09 3.1e-09 1.8e-02 84 SUGP2
48 19 49400634 50767440 1 1 3.9e-07 2.6e-05 1.1e-01 86 PRR12
49 20 36681910 38094711 1 1 3.5e-07 2.1e-09 3.8e-04 65 ACTR5
50 21 36811159 38215923 1 1 3.5e-07 1.7e-07 6.6e-02 88 CBR3
51 22 39192995 43232818 12 3 2.1e-10 1.6e-10 1.2e-02 85 CYP2D7P1 MGAT3 XPNPEP3

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Alzheimer’s Disease (including proxy) 1.0 1 0 0.0 0.00 1.0e+00 CYSTM1
Crohns Disease (2017) 1.2 2 0 0.0 0.00 1.0e+00 GIGYF1 SF3B1
Irritable Bowel Disease (IBD) 1.1 1 1 3.0 0.00 1.0e+00 GIGYF1
Major Depression (MDD) 2.6 2 0 0.0 0.00 1.0e+00 CNNM2 FES
Reaction Time 2.2 4 0 0.0 1.00 1.6e-03 ATG13 C2orf47 IMMP2L RERE
Verbal and Numeric Reasoning (VNR) 2.1 3 1 3.0 0.00 1.0e+00 CDK2AP1 ITIH4-AS1 MGAT3
Breast Cancer 1.6 3 1 3.0 0.00 1.0e+00 FES SUGP2 TOM1L2
Bipolar Disorder 4.8 3 1 3.0 0.00 1.0e+00 CACNA2D4 ITIH4-AS1 LMAN2L
Body Mass Index (BMI) (2010) 2.0 2 0 0.0 0.00 1.0e+00 CNNM2 NT5C2
Coronary Artery Disease (CAD) 2.2 2 0 0.0 0.00 1.0e+00 CNNM2 CYP17A1-AS1
Crohns Disease (2012) 1.3 1 0 0.0 0.00 1.0e+00 SF3B1
Neuroticism 1.8 2 0 0.0 0.00 1.0e+00 RP11-981G7.6 THOC7
Blood Eosinophil Count 1.4 12 8 24.2 -0.04 8.9e-01 AC103965.1 CDK2AP1 GIGYF1 ITIH4-AS1 LMAN2L MAPK3 PPP2R3C RERE SF3B1 SUGP2 TOM1L2 XPNPEP3
Blood Platelet Count 1.1 14 8 24.2 -0.22 4.4e-01 AC011816.1 AC103965.1 ANKRD44 AS3MT CDK2AP1 HIST2H2BF ITIH4-AS1 NT5C2 PCCB PCNX PRR12 SF3B1 SUGP2 TOM1L2
Blood Red Count 1.6 17 11 33.3 0.18 4.8e-01 AC103965.1 ANKRD44 C2orf47 CDK2AP1 CNNM2 CYP17A1-AS1 GIGYF1 ITIH4-AS1 KLC1 MAPK3 NT5C2 PRR12 RILP SF3B1 SUGP2 TMX2 VPS29
Blood White Count 1.2 13 8 24.2 0.19 5.2e-01 AS3MT CNNM2 CYP2D7P1 FES KLC1 MAPK3 MGAT3 NT5C2 PCCB PPP2R3C RERE RILP THOC7
Heel T-Score 1.7 12 8 24.2 0.05 8.9e-01 AC103965.1 ATG13 C2orf82 CDK2AP1 CNNM2 CYP17A1-AS1 DOPEY1 HIST2H2BF KLC1 MAPK3 NT5C2 RERE
BMI 2.4 16 12 36.4 -0.72 1.6e-03 ABCC10 ARL3 BAI1 C2orf47 CNNM2 CPNE7 CYP17A1-AS1 ITIH4-AS1 KLC1 MAPK3 NT5C2 RILP SNX19 TTC14 VPS29 ZDHHC2
Height 1.5 20 18 54.5 -0.29 2.1e-01 AC103965.1 ARL3 AS3MT C2orf82 CBR3 CDK2AP1 CEP170 CYP17A1-AS1 DOPEY1 FES ITIH4-AS1 KLC1 LMAN2L MAPK3 MGAT3 NT5C2 PRR12 SDCCAG8 SUGP2 THOC7
Waist Hip Ratio (WHR) 1.8 10 4 12.1 0.10 7.8e-01 AC103965.1 CDK2AP1 ERCC8 FAM53C FANCL ITIH4-AS1 MGAT3 PCCB PCNX SF3B1
Systolic Blood Pressure 4.3 15 10 30.3 0.39 1.3e-01 ARL3 AS3MT C2orf47 CNNM2 CYP17A1-AS1 CYP2D7P1 FES NT5C2 PPP1R14B RERE RILP SDCCAG8 TOM1L2 TTC14 VPS29
Smoking Status 3.3 8 4 12.1 -0.41 3.1e-01 ARL3 AS3MT CYP17A1-AS1 ERCC8 FES KLC1 NT5C2 RERE
Allergy or Eczema 2.5 8 4 12.1 0.22 5.9e-01 ANKRD44 CDK2AP1 FES PPP2R3C PRR12 PSMA4 RERE SF3B1
Cardiovascular Disease 3.0 10 7 21.2 -0.15 6.8e-01 ATG13 CNNM2 CYP17A1-AS1 FES KLC1 NT5C2 PCCB PCNX RILP SDCCAG8
Hypothyroidism (self reported) 1.2 2 1 3.0 0.00 1.0e+00 GIGYF1 PPP2R3C
Respiratory disease 1.4 2 1 3.0 0.00 1.0e+00 ANKRD44 RERE
Lung FEV1/FVC ratio 1.3 7 2 6.1 -0.73 6.3e-02 AC103965.1 ARL3 CBR3 ITIH4-AS1 MAPK3 PSMA4 RERE
Lung FVC 1.2 8 3 9.1 -0.39 3.5e-01 ABCC10 CPEB1 CPNE7 CYP17A1-AS1 HIST2H2BF MAD1L1 NT5C2 PSMA4
Neuroticism 2.6 7 5 15.2 0.71 5.0e-02 CNNM2 CYP17A1-AS1 FANCL IGSF9B NT5C2 PCCB RERE
Chronotype (morning person) 1.1 1 0 0.0 0.00 1.0e+00 SF3B1
Hair Pigment 1.0 10 7 21.2 -0.44 2.0e-01 CDK2AP1 CPEB1 CPNE7 FAM53C FES GIGYF1 HIST2H2BF KLC1 PCNX XPNPEP3
Tanning 1.8 4 1 3.0 0.43 5.7e-01 AS3MT CPNE7 ERCC8 ITIH4-AS1
Hand grip strength (left) 1.8 5 1 3.0 0.63 2.6e-01 ARL3 CYP17A1-AS1 FES IGSF9B MAPK3
Sensitivity / hurt feelings 2.0 4 0 0.0 -1.00 3.7e-03 FES IGSF9B SUGP2 TOM1L2
Relative age of first facial hair 1.1 1 0 0.0 0.00 1.0e+00 CEP170
Systolic blood pressure, automated reading 3.9 9 6 18.2 -0.54 1.1e-01 CNNM2 CYP17A1-AS1 FES NT5C2 PPP1R14B RERE RILP RP11-981G7.6 TOM1L2
Angina 1.5 1 1 3.0 0.00 1.0e+00 FES
Pack years adult smoking proportion 4.8 2 1 3.0 0.00 1.0e+00 KLC1 PSMA4
Impedance of leg (right) 2.9 14 10 30.3 -0.39 1.7e-01 AC103965.1 C2orf47 CNNM2 CYP17A1-AS1 ERCC8 FES HIST2H2BF ITIH4-AS1 KLC1 MAPK3 NT5C2 RP11-981G7.6 SF3B1 SUGP2
Leg fat-free mass (left) 2.5 14 7 21.2 0.70 3.4e-03 ARL3 AS3MT C2orf47 CDK2AP1 CEP170 CNNM2 CYP17A1-AS1 ERCC8 FES MAPK3 MGAT3 NT5C2 PRR12 VPS29
Trunk fat percentage 1.9 8 5 15.2 -0.16 7.1e-01 AC103965.1 ANKRD44 CPNE7 MAPK3 RERE RILP SF3B1 SNX19
Hand grip strength (right) 1.3 2 1 3.0 0.00 1.0e+00 ARL3 CYP17A1-AS1
Current tobacco smoking 2.3 5 1 3.0 0.32 6.0e-01 ARL3 AS3MT KLC1 RERE RP11-981G7.6
Maternal smoking around birth 2.4 4 0 0.0 0.32 6.8e-01 ARL3 AS3MT KLC1 PSMA4
Fed-up feelings 1.7 1 0 0.0 0.00 1.0e+00 PCCB
Relative age voice broke 1.0 1 0 0.0 0.00 1.0e+00 PCCB
Taking other prescription medications 1.3 1 0 0.0 0.00 1.0e+00 CPNE7
Age when periods started (menarche) 1.9 3 1 3.0 0.00 1.0e+00 ABCC10 DOPEY1 MAPK3
Heel bone mineral density (BMD) T-score, automated (left) 1.8 3 2 6.1 0.00 1.0e+00 DOPEY1 RERE RP11-981G7.6
High blood pressure 3.2 7 5 15.2 0.07 8.8e-01 CNNM2 CYP17A1-AS1 FES NT5C2 PCCB RP11-981G7.6 SDCCAG8
Hayfever, allergic rhinitis or eczema 2.1 4 4 12.1 -0.66 3.4e-01 ANKRD44 PPP2R3C RERE SF3B1
Multivitamins +/- minerals 1.7 1 0 0.0 0.00 1.0e+00 BAI1
Stomach or abdominal pain in last month 1.8 1 0 0.0 0.00 1.0e+00 GIGYF1
Medication: Atenolol 1.9 1 1 3.0 0.00 1.0e+00 FES
Medication: Levothyroxine sodium 1.3 1 0 0.0 0.00 1.0e+00 GIGYF1
Sitting height 1.5 10 5 15.2 0.06 8.6e-01 AC103965.1 C2orf82 CDK2AP1 DOPEY1 FAM53C MGAT3 NT5C2 PRR12 SUGP2 THOC7
Chronic bronchitis/emphysema (father) 2.1 1 1 3.0 0.00 1.0e+00 PSMA4
High blood pressure (mother) 2.8 4 2 6.1 0.98 1.5e-02 CNNM2 CYP17A1-AS1 FES NT5C2
Body mass index (BMI) 2.3 13 6 18.2 0.66 1.5e-02 ARL3 BAI1 C2orf47 CNNM2 CYP17A1-AS1 ITIH4-AS1 KLC1 MAPK3 NT5C2 RILP RP11-981G7.6 SNX19 VPS29
Impedance of leg (left) 2.8 15 9 27.3 -0.35 2.0e-01 AC103965.1 CDK2AP1 CNNM2 CYP17A1-AS1 ERCC8 FES HIST2H2BF ITIH4-AS1 MAPK3 MGAT3 NT5C2 RP11-981G7.6 SF3B1 SUGP2 TOM1L2
Leg predicted mass (left) 2.5 15 7 21.2 0.71 2.0e-03 ARL3 AS3MT C2orf47 CDK2AP1 CEP170 CNNM2 CYP17A1-AS1 ERCC8 FES MAPK3 MGAT3 NT5C2 PRR12 TOM1L2 VPS29
Trunk fat mass 2.1 10 6 18.2 0.89 5.7e-04 AC103965.1 ARL3 C2orf47 CNNM2 CPNE7 CYP17A1-AS1 MAPK3 NT5C2 RILP SNX19
Waist circumference 2.3 9 3 9.1 0.72 2.7e-02 ARL3 BAI1 C2orf47 CYP17A1-AS1 KLC1 MAPK3 PCCB RILP SNX19
Number of incorrect matches in round 2.7 2 1 3.0 0.00 1.0e+00 AS3MT MAPK3
Past tobacco smoking 2.5 4 3 9.1 -0.95 4.8e-02 ARL3 AS3MT CYP17A1-AS1 NT5C2
Alcohol usually taken with meals 1.7 1 0 0.0 0.00 1.0e+00 ERCC8
Nervous feelings 3.5 10 6 18.2 -0.82 2.0e-03 ARL3 AS3MT CNNM2 CYP17A1-AS1 DOPEY1 ITIH4-AS1 MAPK3 NT5C2 PCCB RP11-981G7.6
Frequency of tenseness / restlessness in last 2 weeks 2.4 4 0 0.0 0.43 5.7e-01 CNNM2 CYP17A1-AS1 NT5C2 PCCB
Hearing difficulty/problems with background noise 1.7 1 0 0.0 0.00 1.0e+00 KLC1
Forced vital capacity (FVC) 1.4 5 2 6.1 0.70 1.9e-01 AC103965.1 CEP170 HIST2H2BF PSMA4 TOM1L2
Heel bone mineral density (BMD) T-score, automated (right) 1.7 3 2 6.1 0.00 1.0e+00 DOPEY1 RERE RP11-981G7.6
Qualifications: None of the above 1.6 2 2 6.1 0.00 1.0e+00 CDK2AP1 ERCC8
Financial difficulties in last 2 years 1.1 1 0 0.0 0.00 1.0e+00 KLC1
Mouth/teeth dental problems 1.6 1 0 0.0 0.00 1.0e+00 KLC1
Heart attack 1.7 1 1 3.0 0.00 1.0e+00 FES
Allergy 2.0 6 3 9.1 0.35 4.9e-01 ANKRD44 CDK2AP1 FES PPP2R3C RERE SF3B1
Hayfever/allergic rhinitis (self-reported) 1.4 1 0 0.0 0.00 1.0e+00 SF3B1
Medication: Ramipril 1.9 1 0 0.0 0.00 1.0e+00 FES
Medication: Simvastatin 1.4 1 1 3.0 0.00 1.0e+00 FES
Fluid intelligence score 1.8 2 1 3.0 0.00 1.0e+00 CDK2AP1 MGAT3
Illnesses of siblings 1.4 1 0 0.0 0.00 1.0e+00 FES
Neuroticism score 2.2 4 2 6.1 0.74 2.6e-01 CYP17A1-AS1 IGSF9B PCCB RP11-981G7.6
Weight 2.4 13 8 24.2 0.84 1.8e-04 AC103965.1 ARL3 AS3MT C2orf47 CDK2AP1 CNNM2 CYP17A1-AS1 MAPK3 NT5C2 PRR12 RILP SNX19 VPS29
Impedance of arm (right) 2.5 11 8 24.2 -0.60 5.1e-02 AC103965.1 ANKRD44 ARL3 ERCC8 FAM53C ITIH4-AS1 MAPK3 RP11-981G7.6 SF3B1 SUGP2 VPS29
Arm fat percentage (right) 2.0 11 5 15.2 0.34 3.0e-01 ANKRD44 ARL3 C2orf47 CNNM2 CPNE7 KLC1 MAPK3 NT5C2 RILP SF3B1 SNX19
Trunk fat-free mass 2.3 15 10 30.3 0.76 5.7e-04 ARL3 AS3MT CDK2AP1 CNNM2 CYP17A1-AS1 DOPEY1 ERCC8 FAM53C MAPK3 MGAT3 NT5C2 PPP2R3C PRR12 SF3B1 VPS29
Hip circumference 2.4 14 6 18.2 0.83 2.3e-04 AC103965.1 ARL3 AS3MT BAI1 CDK2AP1 CNNM2 CYP17A1-AS1 ERCC8 ITIH4-AS1 MAPK3 NT5C2 RILP SNX19 VPS29
Alcohol intake versus 10 years previously 1.3 2 0 0.0 0.00 1.0e+00 CDK2AP1 MAPK3
Father's age at death 1.8 2 2 6.1 0.00 1.0e+00 FES PSMA4
Worrier / anxious feelings 4.1 11 9 27.3 -0.76 4.3e-03 ARL3 AS3MT C2orf47 CACNA2D4 CNNM2 CYP17A1-AS1 IGSF9B ITIH4-AS1 NT5C2 PCCB RP11-981G7.6
Frequency of tiredness / lethargy in last 2 weeks 1.8 3 0 0.0 0.00 1.0e+00 FANCL KLC1 PRR12
Forced expiratory volume in 1-second (FEV1) 1.6 3 3 9.1 0.00 1.0e+00 AC103965.1 CEP170 PSMA4
Pulse rate 2.3 2 1 3.0 0.00 1.0e+00 GIGYF1 ITIH4-AS1
Qualifications: A levels/AS levels or equivalent 1.8 3 1 3.0 0.00 1.0e+00 CDK2AP1 ERCC8 MGAT3
Mouth/teeth dental problems: Dentures 2.1 1 0 0.0 0.00 1.0e+00 PSMA4
Asthma 1.3 1 0 0.0 0.00 1.0e+00 RERE
Medication: Cholesterol lowering 1.6 1 1 3.0 0.00 1.0e+00 FES
Lung cancer (father) 2.2 1 1 3.0 0.00 1.0e+00 PSMA4
Illnesses of mother 1.4 1 1 3.0 0.00 1.0e+00 FES
Forced expiratory volume in 1-second (FEV1), Best measure 1.6 3 2 6.1 0.00 1.0e+00 AC103965.1 CEP170 PSMA4
Impedance of arm (left) 2.5 11 6 18.2 -0.57 6.7e-02 AC103965.1 ANKRD44 ARL3 CYP17A1-AS1 ERCC8 ITIH4-AS1 MAPK3 RP11-981G7.6 SF3B1 SUGP2 VPS29
Arm fat mass (right) 2.2 13 3 9.1 0.58 3.7e-02 ARL3 BAI1 C2orf47 CNNM2 CPNE7 CYP17A1-AS1 KLC1 MAPK3 NT5C2 RILP RP11-981G7.6 SNX19 VPS29
Trunk predicted mass 2.3 15 10 30.3 0.76 5.6e-04 ARL3 AS3MT CDK2AP1 CNNM2 CYP17A1-AS1 DOPEY1 ERCC8 FAM53C MAPK3 MGAT3 NT5C2 PPP2R3C PRR12 SF3B1 VPS29
Standing height 1.5 16 8 24.2 0.45 7.9e-02 AC103965.1 ARL3 AS3MT C2orf82 CDK2AP1 CEP170 CYP17A1-AS1 DOPEY1 ITIH4-AS1 KLC1 MAPK3 MGAT3 NT5C2 PPP2R3C PRR12 SDCCAG8
Tense / 'highly strung' 2.5 6 0 0.0 -0.67 1.5e-01 CACNA2D4 CNNM2 MAPK3 NT5C2 PCCB RERE
Seen doctor (GP) for nerves, anxiety, tension or depression 2.1 2 0 0.0 0.00 1.0e+00 FANCL IGSF9B
Birth weight of first child 1.9 3 1 3.0 0.00 1.0e+00 AS3MT FES NT5C2
Peak expiratory flow (PEF) 1.5 3 0 0.0 0.00 1.0e+00 ARL3 PSMA4 RP11-981G7.6
Pulse wave reflection index 1.9 1 0 0.0 0.00 1.0e+00 NT5C2
Qualifications: O levels/GCSEs or equivalent 1.6 1 1 3.0 0.00 1.0e+00 CDK2AP1
Mouth/teeth dental problems: Bleeding gums 1.7 1 0 0.0 0.00 1.0e+00 RP11-981G7.6
Medication: Paracetamol 1.8 1 0 0.0 0.00 1.0e+00 SDCCAG8
Headache pain in last month 1.6 2 2 6.1 0.00 1.0e+00 CEP170 SDCCAG8
Medication for cholesterol, blood pressure or diabetes 2.1 1 1 3.0 0.00 1.0e+00 FES
Hypothyroidism/myxoedema (self-reported) 1.5 2 1 3.0 0.00 1.0e+00 GIGYF1 RP11-981G7.6
Medication: Amlodipine 1.9 1 1 3.0 0.00 1.0e+00 FES
Birth weight 1.9 4 3 9.1 0.44 4.6e-01 CNNM2 CYP17A1-AS1 FES NT5C2
Chronic bronchitis/emphysema (mother) 1.7 1 1 3.0 0.00 1.0e+00 PSMA4
High blood pressure (siblings) 1.5 1 1 3.0 0.00 1.0e+00 FES
Forced vital capacity (FVC), Best measure 1.2 3 1 3.0 0.00 1.0e+00 AC103965.1 CEP170 PSMA4
Body fat percentage 1.9 9 4 12.1 0.11 7.8e-01 AC103965.1 ANKRD44 ARL3 CPNE7 MAPK3 RERE RILP SF3B1 SNX19
Leg fat percentage (right) 1.9 6 2 6.1 0.63 1.8e-01 AC103965.1 ARL3 MAPK3 RERE RILP SNX19
Arm fat-free mass (right) 2.4 14 9 27.3 0.73 2.0e-03 ARL3 AS3MT C2orf82 CDK2AP1 CNNM2 CYP17A1-AS1 ERCC8 FAM53C MAPK3 MGAT3 NT5C2 PPP2R3C SF3B1 VPS29
Comparative body size at age 10 2.0 5 1 3.0 0.98 3.3e-03 ERCC8 MAPK3 SNX19 SUGP2 VPS37A
Worry too long after embarrassment 1.9 2 1 3.0 0.00 1.0e+00 NT5C2 PCCB
Seen a psychiatrist for nerves, anxiety, tension or depression 2.3 2 0 0.0 0.00 1.0e+00 ACTR5 FANCL
Wheeze or whistling in the chest in last year 1.6 3 0 0.0 0.00 1.0e+00 ATG13 MAPK3 RERE
Reason for reducing amount of alcohol drunk: Health precaution 1.5 1 0 0.0 0.00 1.0e+00 ACTR5
Age at first live birth 1.5 2 0 0.0 0.00 1.0e+00 RILP XPNPEP3
Pulse wave peak to peak time 1.8 1 0 0.0 0.00 1.0e+00 AS3MT
Qualifications: College or University degree 2.0 7 4 12.1 -0.30 5.1e-01 ARL3 C2orf82 CDK2AP1 CEP170 ERCC8 KLC1 MGAT3
Emphysema/chronic bronchitis 1.5 1 0 0.0 0.00 1.0e+00 PSMA4
Medication for pain relief, constipation, heartburn 1.8 2 0 0.0 0.00 1.0e+00 CDK2AP1 SDCCAG8
Medication: Blood pressure 2.4 1 1 3.0 0.00 1.0e+00 FES
Angina (self-reported) 1.6 1 1 3.0 0.00 1.0e+00 FES
Mean time to correctly identify matches 2.1 3 0 0.0 0.00 1.0e+00 ATG13 IMMP2L RERE
Whole body fat mass 2.2 9 6 18.2 0.95 6.6e-05 AC103965.1 ARL3 C2orf47 CNNM2 CYP17A1-AS1 MAPK3 NT5C2 RILP SNX19
Leg fat mass (right) 2.3 12 4 12.1 0.83 7.7e-04 AC103965.1 ARL3 AS3MT CNNM2 CYP17A1-AS1 ITIH4-AS1 MAPK3 NT5C2 RILP RP11-981G7.6 SNX19 VPS29
Arm predicted mass (right) 2.3 15 8 24.2 0.74 9.8e-04 ARL3 AS3MT C2orf82 CDK2AP1 CNNM2 CYP17A1-AS1 ERCC8 FAM53C MAPK3 MGAT3 NT5C2 PPP2R3C PRR12 SF3B1 VPS29
Pulse rate, automated reading 2.8 4 2 6.1 -0.85 1.5e-01 AC103965.1 GIGYF1 ITIH4-AS1 VPS29
Alcohol intake frequency. 1.4 3 0 0.0 0.00 1.0e+00 BAI1 CDK2AP1 MAPK3
Comparative height size at age 10 1.8 8 5 15.2 0.58 1.3e-01 AC103965.1 CBR3 CDK2AP1 CYP17A1-AS1 ITIH4-AS1 KLC1 MAPK3 PRR12
Suffer from 'nerves' 2.1 1 0 0.0 0.00 1.0e+00 CYP17A1-AS1
Overall health rating 1.9 5 0 0.0 -0.62 2.7e-01 CPNE7 KLC1 PSMA4 SF3B1 TOM1L2
Medication: Aspirin 1.6 1 1 3.0 0.00 1.0e+00 FES
Hypertension (Self-reported) 3.2 8 5 15.2 0.12 7.7e-01 CNNM2 CYP17A1-AS1 FES NT5C2 PCCB PPP1R14B RP11-981G7.6 SDCCAG8
Illnesses of father: Heart disease 1.8 1 1 3.0 0.00 1.0e+00 FES
Smoking status: Previous 1.7 1 0 0.0 0.00 1.0e+00 ARL3
Forced expiratory volume in 1-second (FEV1), predicted 1.6 2 2 6.1 0.00 1.0e+00 AC103965.1 DOPEY1
Whole body fat-free mass 2.4 17 9 27.3 0.75 3.9e-04 ARL3 AS3MT C2orf47 C2orf82 CDK2AP1 CEP170 CNNM2 CYP17A1-AS1 ERCC8 FAM53C MAPK3 MGAT3 NT5C2 PPP2R3C PRR12 SF3B1 VPS29
Leg fat-free mass (right) 2.5 14 7 21.2 0.71 3.2e-03 ARL3 AS3MT C2orf47 CDK2AP1 CEP170 CNNM2 CYP17A1-AS1 ERCC8 FES MAPK3 MGAT3 NT5C2 PRR12 VPS29
Arm fat percentage (left) 2.0 11 3 9.1 0.22 5.1e-01 ANKRD44 C2orf47 CNNM2 CPNE7 KLC1 MAPK3 NT5C2 RERE RILP SF3B1 SNX19
Average weekly red wine intake 1.2 1 0 0.0 0.00 1.0e+00 CDK2AP1
Loneliness, isolation 1.2 1 0 0.0 0.00 1.0e+00 RERE
Long-standing illness, disability or infirmity 1.7 1 0 0.0 0.00 1.0e+00 KLC1
Friendships satisfaction 1.4 1 0 0.0 0.00 1.0e+00 ZDHHC2
Qualifications: nursing, teaching 1.5 2 1 3.0 0.00 1.0e+00 CDK2AP1 ERCC8
Medication for cholesterol 1.6 1 0 0.0 0.00 1.0e+00 FES
Mineral and other dietary supplements 1.6 1 0 0.0 0.00 1.0e+00 BAI1
Asthma (self-reported) 1.3 1 0 0.0 0.00 1.0e+00 RERE
Medication: Aspirin 1.7 1 1 3.0 0.00 1.0e+00 FES
Illnesses of father: None of the above (group 1) 2.2 1 1 3.0 0.00 1.0e+00 FES
Smoking status: Current 2.3 4 1 3.0 0.52 4.8e-01 ARL3 AS3MT KLC1 NT5C2
Forced expiratory volume in 1-second (FEV1), predicted percentage 1.7 2 1 3.0 0.00 1.0e+00 MAPK3 PSMA4
Whole body water mass 2.4 16 9 27.3 0.74 6.9e-04 ARL3 AS3MT C2orf47 C2orf82 CDK2AP1 CEP170 CNNM2 CYP17A1-AS1 ERCC8 MAPK3 MGAT3 NT5C2 PPP2R3C PRR12 SF3B1 VPS29
Leg predicted mass (right) 2.5 14 7 21.2 0.70 3.3e-03 ARL3 AS3MT C2orf47 CDK2AP1 CEP170 CNNM2 CYP17A1-AS1 ERCC8 FES MAPK3 MGAT3 NT5C2 PRR12 VPS29
Arm fat mass (left) 2.3 13 4 12.1 0.69 8.6e-03 ARL3 BAI1 C2orf47 CNNM2 CPNE7 CYP17A1-AS1 ITIH4-AS1 KLC1 MAPK3 NT5C2 RILP SNX19 VPS29
Number of self-reported non-cancer illnesses 1.3 1 0 0.0 0.00 1.0e+00 TOM1L2
Average weekly champagne plus white wine intake 1.6 1 0 0.0 0.00 1.0e+00 RERE
Miserableness 1.5 2 0 0.0 0.00 1.0e+00 CEP170 RP11-981G7.6
Hearing aid user 1.5 1 0 0.0 0.00 1.0e+00 ERCC8
Medication: Blood pressure 2.6 6 3 9.1 0.10 8.5e-01 CNNM2 CPNE7 FES NT5C2 RILP RP11-981G7.6
Medication: Bendroflumethiazide 1.8 2 1 3.0 0.00 1.0e+00 FES RP11-981G7.6
Illnesses of father: High blood pressure 2.5 1 1 3.0 0.00 1.0e+00 FES
Ever smoked 2.5 5 2 6.1 0.58 3.1e-01 ARL3 AS3MT CDK2AP1 NT5C2 PSMA4
Basal metabolic rate 2.4 16 7 21.2 0.74 7.6e-04 ARL3 AS3MT C2orf47 C2orf82 CDK2AP1 CEP170 CNNM2 CYP17A1-AS1 ERCC8 MAPK3 MGAT3 NT5C2 PPP2R3C PRR12 SF3B1 VPS29
Leg fat percentage (left) 1.9 5 2 6.1 0.62 2.7e-01 ARL3 MAPK3 RERE RILP SNX19
Arm fat-free mass (left) 2.4 14 7 21.2 0.82 1.9e-04 ARL3 AS3MT CDK2AP1 CNNM2 CYP17A1-AS1 ERCC8 FAM53C MAPK3 MGAT3 NT5C2 PPP2R3C PRR12 SF3B1 VPS29
Number of operations (self-reported) 1.2 1 0 0.0 0.00 1.0e+00 ERCC8
Irritability 2.1 1 1 3.0 0.00 1.0e+00 RP11-981G7.6
Risk taking 3.0 4 1 3.0 0.20 8.0e-01 CEP170 KLC1 PCCB PSMA4
Diastolic blood pressure, automated reading 3.7 10 9 27.3 -0.13 7.2e-01 CDK2AP1 CEP170 CNNM2 CYP17A1-AS1 FES GIGYF1 NT5C2 RERE RP11-981G7.6 SDCCAG8
Unable to work because of sickness or disability 2.1 1 0 0.0 0.00 1.0e+00 SF3B1
Vascular/heart problems diagnosed by doctor 3.3 9 4 12.1 -0.02 9.7e-01 CNNM2 CYP17A1-AS1 FES NT5C2 PCCB PPP1R14B RILP RP11-981G7.6 TOM1L2
Heart attack/myocardial infarction (self-reported) 1.6 1 1 3.0 0.00 1.0e+00 FES
Heart disease (siblings) 1.4 1 0 0.0 0.00 1.0e+00 FES
Pack years of smoking 4.5 1 1 3.0 0.00 1.0e+00 PSMA4
Impedance of whole body 2.9 15 11 33.3 -0.61 1.6e-02 AC103965.1 ANKRD44 ARL3 CACNA2D4 CNNM2 CYP17A1-AS1 ERCC8 ITIH4-AS1 MAPK3 NT5C2 RERE RP11-981G7.6 SF3B1 SUGP2 VPS29
Leg fat mass (left) 2.3 12 4 12.1 0.94 4.4e-06 ABCC10 ARL3 AS3MT C2orf47 CNNM2 CYP17A1-AS1 ITIH4-AS1 MAPK3 NT5C2 RILP SNX19 VPS29
Arm predicted mass (left) 2.4 13 7 21.2 0.83 2.7e-04 ARL3 AS3MT CDK2AP1 CNNM2 CYP17A1-AS1 ERCC8 MAPK3 MGAT3 NT5C2 PPP2R3C PRR12 SF3B1 VPS29

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 19 0.564 2.31
GTEx Adipose Visceral Omentum 12 0.607 2.33
GTEx Adrenal Gland 8 0.565 2.24
GTEx Artery Aorta 17 0.590 2.29
GTEx Artery Coronary 4 0.347 2.28
GTEx Artery Tibial 19 0.523 2.32
GTEx Brain Caudate basal ganglia 3 0.337 2.23
GTEx Brain Cerebellar Hemisphere 4 0.275 2.25
GTEx Brain Cerebellum 10 0.519 2.46
GTEx Brain Cortex 7 0.695 2.31
GTEx Brain Frontal Cortex BA9 2 0.224 2.36
GTEx Brain Hippocampus 1 0.196 2.41
GTEx Brain Hypothalamus 3 0.526 2.12
GTEx Brain Nucleus accumbens basal ganglia 5 0.595 2.27
GTEx Brain Putamen basal ganglia 2 0.327 2.22
GTEx Breast Mammary Tissue 17 0.892 2.52
GTEx Breast Mammary Tissue (Male) 7 0.613 2.36
GTEx Breast Mammary Tissue (Female) 11 0.700 2.29
GTEx Cells EBV-transformed lymphocytes 8 0.578 2.51
GTEx Cells Transformed fibroblasts 24 0.588 2.38
GTEx Colon Sigmoid 9 0.635 2.35
GTEx Colon Transverse 11 0.549 2.52
GTEx Esophagus Gastroesophageal Junction 8 0.575 2.40
GTEx Esophagus Mucosa 14 0.433 2.41
GTEx Esophagus Muscularis 22 0.702 2.31
GTEx Heart Atrial Appendage 5 0.325 2.34
GTEx Heart Left Ventricle 9 0.606 2.35
GTEx Liver 4 0.573 2.42
GTEx Lung 14 0.504 2.35
GTEx Muscle Skeletal 9 0.320 2.29
GTEx Nerve Tibial 21 0.501 2.26
GTEx Ovary 4 0.450 2.39
GTEx Pancreas 8 0.503 2.58
GTEx Pituitary 8 0.733 2.37
GTEx Prostate 5 0.618 2.62
GTEx Skin Not Sun Exposed Suprapubic 13 0.542 2.34
GTEx Skin Sun Exposed Lower leg 8 0.228 2.33
GTEx Small Intestine Terminal Ileum 3 0.676 2.57
GTEx Spleen 11 0.799 2.42
GTEx Stomach 6 0.425 2.29
GTEx Testis 24 0.780 2.52
GTEx Thyroid 20 0.516 2.38
GTEx Uterus 0 0.000 2.22
GTEx Vagina 2 0.327 2.20
GTEx Whole Blood 13 0.673 2.35
METSIM Adipose 11 0.244 2.14
NTR Blood 7 0.294 2.14
ROSMAP Brain Pre-frontal Cortex 17 0.396 2.36
YFS Blood 16 0.351 2.12
CommonMind Brain Pre-frontal Cortex 15 0.284 2.25
TCGA Breast Tumor 3 0.397 2.42
TCGA Breast Normal 15 0.364 2.07
TCGA Ovarian Tumor 10 0.347 2.05
TCGA Prostate Tumor 13 0.384 2.18